Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 4Sarcoma 4Genitourinary 4Gastrointestinal 4CNS 4Other solid neoplasm 3Endocrine 3Dermatologic 3Breast 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2NET 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Capecitabine 47Radiotherapy 46Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
vatalanib × Tumor-Agnostic × Clear all
NCT00731861 2014-09-11

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Indiana University

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT00226005 2012-05-09

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Research Team

Phase 2 Completed
67 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT00171587 2009-11-19

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

Novartis

Phase 1/2 Completed
22 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

SCRI Development Innovations, LLC

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡